Björn Cochlovius

Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway.

Eleva GmbH develops biotechnology products and services. It offers Moss-aGal, Moss-GBA, Moss-FH, contract development and production, developmental pipeline, and technology transfer. The company was founded by Ralf Reski and Gunther Neuhaus in 1999 and is headquartered in Heilbronn, Germany.

Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark.

Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom.

Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany.